Minimal residual disease (MRD) testing has rapidly evolved from an emerging oncology innovation into a critical component of precision cancer care. As adoption accelerates across hematologic malignancies and solid tumors, laboratories, clinicians, and payers are facing a new reality: The operational and reimbursement infrastructure supporting MRD testing has not kept pace with the science.
While the clinical promise of MRD testing is substantial, including earlier detection of recurrence, treatment monitoring, therapy optimization, and potential reductions in unnecessary interventions, the pathway to sustainable reimbursement remains highly fragmented and operationally complex.
For laboratories offering MRD assays, success increasingly depends not only on scientific validity, but also on operational discipline, reimbursement strategy, and market access readiness.
A rapidly expanding clinical category
MRD testing is experiencing significant growth as oncologists increasingly incorporate longitudinal molecular monitoring into patient management strategies. Advances in next-generation sequencing, circulating tumor DNA analysis, and personalized tumor-informed assays have expanded MRD applications across multiple disease states.
At the same time, coverage policies continue to evolve unevenly across both Medicare and commercial payers. Medicare pathways under Molecular Diagnostic Services (MolDX) and other Medicare Administrative Contractors remain dynamic, while commercial payers often apply differing medical necessity criteria, covered indications, frequency limitations, and documentation requirements.
This disconnect between clinical adoption and reimbursement standardization has created substantial operational pressure for laboratories. The challenge is no longer simply whether a laboratory can clinically perform MRD testing but whether it can operationalize the reimbursement infrastructure necessary to support long-term sustainability.
Operational complexity is increasing faster than the science
Historically, many molecular laboratories focused primarily on analytical validation and demonstrating clinical utility. Today, operational scalability has become equally important. MRD testing presents a uniquely difficult reimbursement environment because these assays are highly personalized, longitudinal in nature, and often performed repeatedly throughout a patient’s treatment journey. Unlike traditional single-event diagnostic testing, MRD assays frequently require serial monitoring across multiple timepoints, creating additional layers of utilization management and reimbursement scrutiny.
Many payers are now implementing increasingly restrictive frequency limitations or policies that effectively limit reimbursement for certain MRD assays to a single test per patient lifetime. Operationally, this creates a significant burden because laboratories may need to retrospectively evaluate historical claims activity, prior testing utilization, and previous molecular testing records before determining whether a new specimen can be tested and billed compliantly. This level of longitudinal patient tracking introduces operational demands that many laboratories were not originally designed to manage.
Recent reimbursement trend analyses discussed during MRD industry forums and operational reviews further illustrate the growing complexity laboratories are facing. Denials are increasingly concentrated around medical necessity interpretation, frequency limitations, prior authorization discrepancies, insufficient clinical documentation, and duplicate or serial testing concerns. Laboratories are also reporting increased scrutiny related to repeat testing intervals and payer interpretation of longitudinal monitoring protocols, particularly as MRD testing expands beyond hematologic malignancies into broader oncology applications.
As a result, organizations are being forced to invest in more sophisticated data infrastructure, workflow automation, and reimbursement intelligence capabilities to ensure compliance while minimizing unnecessary denials.
Policy fragmentation continues to intensify
One of the most significant barriers facing MRD laboratories today is the growing inconsistency among commercial payer medical policies. Coverage criteria often vary dramatically across plans, even for the same assay and clinical indication. Some payers may cover serial monitoring for specific cancer types while others continue to classify similar testing as experimental and investigational. Frequency limitations may differ substantially, and prior authorization requirements often vary not only by payer, but also by individual benefit plans.
Compounding the issue is the reality that policy language frequently lags behind emerging clinical evidence and evolving oncology guidelines. Laboratories are therefore operating in an environment where clinical adoption may outpace reimbursement policy modernization.
Operationally, this means laboratories must maintain near real-time surveillance of changing medical policies, coverage updates, prior authorization requirements, and utilization management rules across a growing number of commercial and governmental payers. Manual policy monitoring processes are becoming increasingly unsustainable, particularly for organizations operating nationally across multiple oncology service lines.
This fragmentation creates downstream operational instability throughout the revenue cycle. Laboratories may experience inconsistent adjudication outcomes for identical testing scenarios depending on payer, plan structure, or regional policy interpretation. In many cases, reimbursement teams must manually review policies and supporting documentation on a case-by-case basis before claims can even be submitted.
To address this challenge, many laboratories are beginning to adopt AI-driven policy monitoring tools, intelligent workflow automation, and centralized reimbursement intelligence platforms designed to identify policy changes and proactively operationalize compliance requirements.
Documentation requirements are expanding
The reimbursement scrutiny surrounding MRD testing has also significantly increased the documentation burden placed on laboratories and ordering providers. Payers increasingly require detailed clinical records to support medical necessity, including pathology confirmation, treatment history, molecular profiling results, recurrence risk assessments, therapy monitoring rationale, and evidence supporting longitudinal testing intervals.
For many laboratories, reimbursement success now depends on obtaining complete and accurate documentation before testing is performed rather than attempting to resolve deficiencies after a denial occurs. This represents a major operational shift for revenue cycle management teams, which historically functioned more independently from laboratory operations and provider engagement workflows.
Organizations are also seeing increased requests for historical patient testing timelines, prior molecular testing records, and longitudinal treatment documentation to validate repeat MRD testing frequency. In some cases, laboratories are being required to demonstrate why additional MRD testing was clinically necessary despite prior testing already having been performed. These requirements can create significant administrative burdens for both laboratories and providers, particularly when medical records are fragmented across multiple treatment sites and electronic health record systems.
Today, successful MRD reimbursement strategies require close coordination between laboratory operations, billing teams, provider support staff, utilization management personnel, and reimbursement specialists. Organizations are increasingly building integrated pre-bill review workflows that combine policy validation, documentation intake, authorization management, and automated claim review processes into a unified operational model.
Coding, billing, and denial management continue to evolve
Coding and billing complexity remains another significant challenge within the MRD landscape. As additional assays enter the market and new proprietary laboratory analyses (PLA) codes are introduced, laboratories must continuously evaluate how coding methodologies align with varying payor billing expectations.
Questions surrounding appropriate CPT or PLA code utilization, MolDX registration requirements, Z-Code alignment, frequency limitations, and evolving National Correct Coding Initiative edits continue to create operational uncertainty.
At the same time, denial activity itself is becoming more sophisticated. Laboratories are no longer facing only straightforward non-covered service denials. Increasingly, denials are tied to nuanced interpretations of medical necessity, documentation sufficiency, serial testing frequency, prior authorization discrepancies, duplicate testing concerns, and clinical utility validation.
Industry discussions surrounding MRD reimbursement trends have also highlighted the growing prevalence of denials categorized as experimental or investigational despite increasing clinical adoption and expanding evidence development. This disconnect between evolving clinical practice and reimbursement policy maturation continues to create uncertainty for laboratories attempting to scale MRD testing programs nationally.
This evolution has fundamentally changed the appeals process. Generic appeal templates are often insufficient in the current environment. Successful laboratories are increasingly leveraging evidence libraries, denial analytics, automated appeal generation technologies, and policy intelligence tools to build more strategic and data-driven appeals processes capable of defending not only the assay itself, but also the timing, frequency, and longitudinal clinical rationale supporting repeated MRD testing.
Reimbursement intelligence is becoming a competitive differentiator
As MRD testing continues to mature, reimbursement intelligence is emerging as a critical competitive differentiator. Laboratories that can proactively monitor policy changes, benchmark reimbursement performance, identify denial trends, and operationalize compliance workflows will be significantly better positioned to scale sustainably in the precision oncology market.
Increasingly, laboratories are investing in integrated reimbursement ecosystems that combine policy intelligence, automated workflow management, denial analytics, prior authorization optimization, revenue integrity monitoring, and longitudinal patient testing visibility. These operational capabilities are becoming just as important as the underlying clinical science.
Organizations that can identify reimbursement friction points early, adapt workflows dynamically, and proactively engage providers regarding documentation requirements will likely experience improved financial sustainability and reduced administrative burden. Conversely, laboratories lacking scalable reimbursement infrastructure may struggle to maintain profitability despite strong clinical demand for MRD testing.
The laboratories most likely to succeed in the evolving MRD landscape will not simply be those with the most innovative assays. They will be the organizations capable of aligning scientific advancement with operational scalability, reimbursement sustainability, and sophisticated market access strategies.
Looking ahead with MRD testing reimbursement
MRD testing represents one of the most promising and transformative areas of precision oncology. However, it also highlights a broader challenge facing advanced diagnostics across healthcare: Innovation is increasingly constrained not by scientific capability, but by operational and reimbursement complexity.
As payoes continue refining utilization management strategies and laboratories expand personalized longitudinal testing models, operational readiness will become essential to financial sustainability. The future success of MRD testing will depend not only on continued clinical evidence generation, but also on the healthcare industry’s ability to modernize reimbursement infrastructure, improve policy consistency, and develop scalable operational frameworks capable of supporting the next generation of precision diagnostics.